Metavalis Inc. Unveils Next Gen saRNA Pipelines Powered by A.L.I.C.E. Cyber Intelligence

BRANSON, Mo. - Aug. 16, 2026 - PRLog -- Metavalis Inc, a biotechnology company specializing in self amplifying RNA saRNA platforms, today announced significant advancements across its deep tech research and development pipeline. By leveraging first principles engineering and high throughput computational modeling, the company is accelerating the development of next generation therapeutics targeting systemic cellular resilience, high fidelity neuro digital data structures, and advanced biological preservation.

At the core of the R&D update is Metavalis's work in systemic genomic repair and cellular radioprotection. Utilizing transient self amplifying RNA architectures, researchers are engineering platforms designed to instruct human cells to rapidly upregulate endogenous DNA repair enzymes on demand. By driving the temporary overexpression of advanced damage suppressor proteins, the therapeutic approach aims to establish an active biological buffer capable of mitigating severe ionizing radiation and cellular degradation.

Alongside its genomic initiatives, Metavalis is exploring foundational models in cellular stasis and neural data preservation. The company is investigating RNA transcribed metabolic suppressants and cellular cryoprotectants inspired by biological mechanisms found in extremophile organisms to prevent ice crystallization during sub zero preservation. Concurrently, Metavalis's neuro digital division is actively modeling non destructive molecular scanning pathways designed to map and translate complex connectome states into secure, stable data structures for whole brain research.

These deep tech milestones are accelerated through Metavalis's proprietary cyber intelligence infrastructure, known as A.L.I.C.E. By executing advanced in silico molecular simulations, the platform calculates millions of RNA permutations and structural folding dynamics in real time, validating therapeutic candidates prior to physical wet lab synthesis.

"Our objective is to remove the traditional latency inherent in conventional biotechnology workflows," stated Jordan Bekemeier, Founder and Chief Executive Officer of Metavalis Inc. "By deploying high density computational models alongside targeted saRNA architectures, we are engineering therapeutic platforms with absolute precision and speed."

Follow On Crunchbase: https://www.crunchbase.com/organization/metavalis